This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

New Data For Jakafi® (ruxolitinib) Presented At The 2012 American Society Of Hematology Annual Meeting

Stocks in this article: INCY

The slides used during the presentations can be accessed at: 2012 ASH Oral_Verstovsek_C-I and 2012 ASH Oral_Cervantes_C-II.

  • Verstovsek, S, et al. Long-term efficacy and safety results from a Phase II study of ruxolitinib in patients with polycythemia vera.

In a Phase II clinical trial of patients (n=34) with polycythemia vera (PV) who are resistant or intolerant to hydroxyurea, ruxolitinib treatment resulted in clinical benefit by providing durable overall response rates by modified European Leukemia Net criteria as well as ameliorating symptoms commonly associated with PV, such as itching, night sweats and bone pain. Overall response was achieved in 97 percent of patients at week 24. Of these responders, 74 percent maintained overall response at week 144. Anemia and thrombocytopenia (primarily grade 1) were the most common adverse events.

The slides used during the presentation can be accessed at: 2012 ASH Oral_Verstovsek_PV.

Other data related to Jakafi presented orally at ASH include:

  • Talpaz, M, et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 10 9 /L): A comparison to patients with normal or high starting platelet counts. 2012 ASH Oral_Talpaz
  • Harrison, C, et al. EXPAND: a Phase 1b, open-label, dose-finding study of ruxolitinib in patients with myelofibrosis and baseline platelet counts between 50 × 10 9 /L and 99 × 10 9 /L. 2012 ASH Oral_Harrison
  • Vannucchi, A, et al. Reductions in JAK2 V617F allele burden with ruxolitinib treatment in COMFORT-II, a Phase III study comparing the safety and efficacy of ruxolitinib with best available therapy. 2012 ASH Oral_Vannucchi

The following presentations related to Jakafi were exhibited during poster sessions at ASH:

  • Mesa, R, et al. Clinical benefits of ruxolitinib therapy in myelofibrosis patients with varying degrees of splenomegaly and symptoms. 2012 ASH Poster #1727
  • Mesa, R, et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib-treated patients with myelofibrosis from COMFORT-I. 2012 ASH Poster #1733
  • McMullin, M, et al. The use of erythropoietic-stimulating agents with ruxolitinib in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis. 2012 ASH Poster #2838
  • Verstovsek, S, et al. Effect of ruxolitinib on the incidence of splenectomy in patients with myelofibrosis: A retrospective analysis of data from ruxolitinib clinical trials. 2012 ASH Poster #2847
  • Ouagari, K, et al. Cost-effectiveness of ruxolitinib versus best-available therapy for medical treatment of myelofibrosis: Canadian societal perspective. 2012 ASH Poster #4255
  • Barosi, G, et al. An individual patient supply program for ruxolitinib for the treatment of patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis. 2012 ASH Poster #2844

About the Webcast

Incyte will host an investor meeting to discuss the new Jakafi data being presented at ASH. The presentation will be webcast live at 8:45 p.m. EST on December 10, 2012, and can be accessed at under Investor Relations, Events and Webcasts. A replay of the event will be available for 60 days.

About Jakafi

Jakafi is a prescription medicine used to treat people with intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF.

3 of 6

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs